Abstract: The invention relates to a method with biofeedback for training muscles of the pelvic floor, applicable to the treatment of urinary incontinence, fecal incontinence and prolapse of pelvic organs, using a portable electronic device for capturing, by means of sensors, EMG signals relating to abdominal activity and the area to be treated during muscle exercises, said device providing results visually and/or acoustically, the method comprising: placing a vaginal or rectal sensor (10) and two sensors (11) in the lower abdominal area, performing exercises working the muscles of the pelvic floor, providing evaluation of the exercises performed and storing results. The user places the sensors herself, the device evaluating the correct placement of the sensors indicating to the user that the suitable position has been reached through said acoustic and/or visual means, and performing a step prior to the exercises for acquiring muscle tone.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.

Abstract: The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hs

Abstract: A bioreactor for cell co-culture having at least first and second cell culture chambers which are separated by a porous membrane. The membrane has at least one sealing gasket integrated in the membrane and being integral therewith. The sealing gasket defines a closed perimeter delimiting a first cell culture area.

Abstract: The method comprises identifying, in a 3D volume, a zone of a first type (H), a zone of a second type (BZ) and a zone of a third type (C) and: —automatically identifying as a candidate channel (bz) a path running through the zone of a second type (BZ) and extending between two points of the zone of a first type (H); and—automatically performing, on a topological space (H_and_BZ_topo), homotopic operations between the candidate channel (bz) and paths (h) running only through the zone of a first type (H), and if the result of said homotopic operations is that the candidate channel (bz) is not homotopic to any path running only through the zone of a first type (H) identifying the candidate channel (bz) as a constrained channel. The computer program product implements the steps of the method of the invention.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer.

Abstract: The present invention concerns subject matter connected to or making use of IgLON5, IgLON5 fragments and variants of IgLON5 and IgLON5-fragments. In particular the present invention relates to a use of a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof for the diagnosis of a disease, in vitro methods for diagnosing such a disease, a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof or a nucleic acid encoding said polypeptide for use in the treatment of a disease, a pharmaceutical composition comprising such polypeptide, a method for treating such a disease, an autoantibody binding to IgLON5, an IgLON5-fragment or a variant thereof, a method for isolating such autoantibody, a medical or diagnostic device comprising such autoantibody or such polypeptide and a test kit for the diagnosis of a disease, which test kit comprises such autoantibody and/or such polypeptide.

Abstract: The present invention relates to the use of photolyase enzymes to reduce or improve subclinical skin field cancerization associated with actinic keratosis or non-melanoma skin cancer (NMSC) and methods for the therapeutic treatment of subclinical field cancerization associated with actinic keratosis and/or non-melanoma skin cancer (NMSC).

Abstract: A portable and low-cost tool for testing a VOR and oculomotor functions. Such a tool is achieved by programming a smartphone for use in performing such testing. Described herein are computer executable programs for assessing vestibular-ocular reflex including visual acuity and oculomotor function.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The methods comprise: a) obtaining a 3D volume of the object containing two different sub-volumes identified as: well-defined zone (S) and not-well-defined zone (BZ) sub-volumes; b) generating well-defined zone (S) and not-well-defined zone (BZ) patches from the two sub-volumes; c) automatically identifying the possible channels by means of automatically obtaining candidate channels regions (CCR), dilating the perimeters of the well-defined zone (S) patches. The method includes embodiments for a layered approach, an EAM polygonal mesh approach and a volume approach. The computer program product is adapted to implement part or all of the steps of the method of the invention. The EAM system comprises computing navigation means implementing the method of the invention.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: The present invention provides methods for selecting an individual with psoriasis (Ps) or psoriatic arthritis (PsA) who should receive or who is likely to respond to a treatment with an anti-tumor necrosis factor alpha (anti-TNF?) therapy. In addition, provided herein are methods for selecting an individual with Ps or PsA who should receive or who is likely to respond to a therapy that is not an anti-TNF? therapy, e.g., a non-anti-TNF? therapy for the treatment of Ps or PsA. Specifically, the methods of the present invention relate to detecting the presence of distinct alleles of the PDE3A-SLCO1C1 locus which are associated with a clinical response to an anti-TNF? therapy or a non-anti-TNF therapy in patients with Ps or PsA.

Abstract: This invention provides methods for predicting response to anti-TNF? biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of PIK3CD as a biomarker, and optionally also determining the level of expression of CX3CL1 as a second biomarker. The invention additionally provides kits for carrying out the methods described.

Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

Abstract: The present invention is related to 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, to the preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in the treatment and/or prevention of a non-Hodgkin's lymphoma.

Abstract: The method comprises identifying, in a 3D volume, a zone of a first type (H), a zone of a second type (BZ) and a zone of a third type (C) and:—automatically identifying as a candidate channel (bz) a path running through the zone of a second type (BZ) and extending between two points of the zone of a first type (H); and—automatically performing, on a topological space (H_and_BZ_topo), homotopic operations between the candidate channel (bz) and paths (h) running only through the zone of a first type (H), and if the result of said homotopic operations is that the candidate channel (bz) is not homotopic to any path running only through the zone of a first type (H) identifying the candidate channel (bz) as a constrained channel. The computer program product implements the steps of the method of the invention.